Erlotinib
Erlotinib plus cisplatin-based chemoradiation promising for cervical cancer
March 11, 2014Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
Erlotinib doesn't hurt but doesn't help standard head-and-neck therapy
March 19, 2013Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
Targeted treatment of resistant cancer may improve progression-free survival with some drugs
December 19, 2012Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.
Veristrat predicts response but not survival benefit from NSCLC treatment
October 17, 2012The plasma test VeriStrat can predict response but not survival benefit from erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
New tool reveals individual tumor cell reactions to therapy
September 06, 2012Time-lapse imaging, analytical tools, and software are combined to provide a detailed picture of a single tumor cell's response to a cancer drug.
Study demonstrates cost-effectiveness of erlotinib treatment
March 31, 2010Erlotinib is a marginally cost-effective treatment for patients with advanced non-small cell lung cancer, according to the results of an economic analysis published in the Journal of the National Cancer Institute (2010;102(5):298-306).
Sign Up for Free e-newsletters
ONA Articles
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Recommended Therapies for Polycythemia Vera Underused
- FDA Grants Approval to New Treatment for Acute Myeloid Leukemia
- Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma
- Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety
- Counseling Patients on Oral Chemotherapy
- Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit
- Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Expression of Chemerin Correlates With a Poor Prognosis in Female Breast Cancer Patients
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Recommended Therapies for Polycythemia Vera Underused
- Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
- Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |